Total Payments
$217,376
2024 Payments
$17.90
Companies
17
Transactions
174
Payment Breakdown by Category
Research$199,896 (92.0%)
Consulting$13,298 (6.1%)
Travel$2,844 (1.3%)
Food & Beverage$1,338 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $199,896 | 105 | 92.0% |
| Consulting Fee | $13,298 | 4 | 6.1% |
| Travel and Lodging | $2,844 | 17 | 1.3% |
| Food and Beverage | $1,338 | 48 | 0.6% |
Payments by Type
Research
$199,896
105 transactions
General
$17,480
69 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Glenmark Pharmaceuticals Inc. | $135,140 | 80 | $0 (2019) |
| Ichnos Sciences Inc. | $36,450 | 7 | $0 (2022) |
| Eli Lilly and Company | $18,120 | 28 | $0 (2023) |
| PFIZER INC. | $10,791 | 7 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,500 | 2 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $4,641 | 9 | $0 (2018) |
| MannKind Corporation | $1,950 | 1 | $0 (2018) |
| Allergan Inc. | $1,424 | 11 | $0 (2019) |
| Celgene Corporation | $936.39 | 4 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $165.36 | 14 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.90 | 1 | GlaxoSmithKline, LLC. ($17.90) |
| 2023 | $10,824 | 8 | PFIZER INC. ($10,791) |
| 2022 | $14,539 | 5 | Ichnos Sciences Inc. ($13,939) |
| 2021 | $7,151 | 2 | Ichnos Sciences Inc. ($7,151) |
| 2020 | $32,064 | 7 | Eli Lilly and Company ($16,704) |
| 2019 | $126,359 | 78 | Glenmark Pharmaceuticals Inc. ($124,386) |
| 2018 | $26,166 | 53 | Glenmark Pharmaceuticals Inc. ($10,754) |
| 2017 | $256.99 | 20 | SANOFI-AVENTIS U.S. LLC ($165.36) |
All Payment Transactions
174 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | GlaxoSmithKline, LLC. | BEXSERO (Biological), PEDIARIX, ROTARIX | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: VACCINES | ||||||
| 12/27/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,220.08 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 11/16/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,388.04 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 10/12/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,220.08 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 09/21/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $4,276.51 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 08/24/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $342.10 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $1,844.60 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 03/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $32.09 | Research |
| Study: A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $291.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $190.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 03/10/2022 | Boston Scientific Corporation | General - Pain Management (Device) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: General - Pain Management_NMD | ||||||
| 02/17/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $98.41 | General |
| Category: Immunology | ||||||
| 02/07/2022 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $13,938.96 | Research |
| Study: ISB830-204 | ||||||
| 03/23/2021 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $5,083.63 | Research |
| Study: GBR830-204 | ||||||
| 03/01/2021 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $2,067.77 | Research |
| Study: GBR830-204 | ||||||
| 09/01/2020 | Ichnos Sciences Inc. | GBR830-204 (Drug) | — | Cash or cash equivalent | $1,864.99 | Research |
| Study: GBR830-204 • Category: GBR830-204 | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $145.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $142.50 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 07/20/2020 | Ichnos Sciences Inc. | GBR830-204 (Drug) | — | Cash or cash equivalent | $5,320.30 | Research |
| Study: GBR830-204 • Category: GBR830-204 | ||||||
| 04/07/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $16,416.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 03/12/2020 | Ichnos Sciences Inc. | GBR830-204 (Drug) | — | Cash or cash equivalent | $732.00 | Research |
| Study: GBR830-204 • Category: GBR830-204 | ||||||
| 01/21/2020 | Ichnos Sciences Inc. | GBR830-204 (Drug) | — | Cash or cash equivalent | $7,442.40 | Research |
| Study: GBR830-204 • Category: GBR830-204 | ||||||
| 11/13/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.58 | General |
| 11/12/2019 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $764.80 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis (AD) | Glenmark Pharmaceuticals Inc. | $124,386 | 50 |
| GBR830-204 | Ichnos Sciences Inc. | $22,511 | 6 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $16,749 | 3 |
| ISB830-204 | Ichnos Sciences Inc. | $13,939 | 1 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $10,791 | 7 |
| A Randomized Double Blind Placebo Controlled Parallel Group Dose Ranging Study Investigating the Efficacy Safety Pharmacokinetics and Pharmacodynamics of GBR830 Administered to Adult Subjects with Moderate to Severe Atopic Dermatitis AD | Glenmark Pharmaceuticals Inc. | $10,754 | 30 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $436.50 | 2 |
| 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS | Allergan Inc. | $297.50 | 5 |
| A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $32.09 | 1 |
About Dr. Mark Mckenzie, MD
Dr. Mark Mckenzie, MD is a Internal Medicine healthcare provider based in Chattanooga, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821064122.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Mckenzie, MD has received a total of $217,376 in payments from pharmaceutical and medical device companies, with $17.90 received in 2024. These payments were reported across 174 transactions from 17 companies. The most common payment nature is "" ($199,896).
Ad
Practice Information
- Specialty Internal Medicine
- Location Chattanooga, TN
- Active Since 02/27/2006
- Last Updated 12/30/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821064122
Products in Payments
- GBR830-204 (Drug) $15,360
- ZAVZPRET (Drug) $10,791
- AFREZZA (Drug) $1,950
- CC-90001 (Drug) $936.39
- TOUJEO (Drug) $124.79
- DUPIXENT (Biological) $98.41
- Victoza (Drug) $48.52
- SOLIQUA (Drug) $40.57
- TRULICITY (Drug) $28.01
- General - Pain Management (Device) $20.46
- BEXSERO (Biological) $17.90
- XIFAXAN (Drug) $15.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chattanooga
Dr. Krishnendu Bhadra, Md, MD
Internal Medicine — Payments: $423,314
Internal Medicine $423,314
Dr. Michael Czarnecki, Md, MD
Internal Medicine — Payments: $417,472
Internal Medicine $417,472
Selcuk Tombul, Do, DO
Internal Medicine — Payments: $317,513
Internal Medicine $317,513
Dr. Matthew Wiisanen, Md, MD
Internal Medicine — Payments: $140,499
Internal Medicine $140,499
Eugene Ryan, Md, MD
Internal Medicine — Payments: $78,046
Internal Medicine $78,046
Dr. Maighan Seagrove, D.o, D.O
Internal Medicine — Payments: $64,768
Internal Medicine $64,768